NCT04361058 2023-12-05Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideSCRI Development Innovations, LLCPhase 1 Withdrawn
NCT04044209 2022-01-20A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDSYale UniversityPhase 2 Withdrawn